BioSpace News Archive

Business

Cambridge Research Biochemicals to Support Preclinical Study on Treatment for Vision-Damaging Eye Disease

Cambridge Research Biochemicals® will support evaluation of a potential new treatment approach for Fuchs Dystrop.

May 23, 2018

·

4 min read

Grail Raises $300 Million from China Investors for Early Cancer Diagnostics

Grail announced a $300 million C financing. Since early 2016, Grail has raised over $1.5 billion.

May 23, 2018

·

1 min read

Drug Development

Berlin Cures Announces Formation of Scientific Advisory Board

Drug developer Berlin Cures today announced the formation of a Scientific Advisory Board (SAB) and the appointment of its first two members, Prof. Beda M. Stadler and Prof. Wilhelm Vetter.

May 23, 2018

·

4 min read

Drug Development

Robocath demonstrates safety and efficacy of its R-OneTM medical robotic platform

Robocath announces during the EuroPCR congress that its first robotic solution, R-OneTM, met all its primary efficacy and safety endpoints in the first pre-clinical study.

May 23, 2018

·

2 min read

Policy

ReCor Medical Announces RADIANCE-HTN SOLO Hypertension Study Meets Primary Efficacy Endpoint, Pivotal Study Submission, and New Principal Investigator

ReCor Medical announced today that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients.

May 23, 2018

·

4 min read

Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform

--Biologics Expert Paul Parren Joins as Head of R&D--

May 23, 2018

·

6 min read

Business

ProSciento Appoints Pete Nieto as Vice President of Business Development

Nieto joins ProSciento from the CRO PPD, where he served as Executive Director of Early Phase Business Development.

May 23, 2018

·

3 min read

Biotech Bay

Three Arch’s shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and Industry Ventures

The Three Arch funds that held the AcelRx shares were each formed between 1999 and 2004 and are at the end of their respective terms.

May 23, 2018

·

4 min read

Business

Translate Bio Names John R. Schroer, CFA, Chief Financial Officer

Mr. Schroer brings expertise in financial strategy and analysis and strong industry relationships to Translate Bio.

May 23, 2018

·

2 min read

FDA

Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease

Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE SierraTM, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system.

May 23, 2018

·

4 min read